Novel Diagnosis and Treatment Techniques for Chronic Hepatitis, Hepatic Fibrosis, and Related Liver Cancer

Professor Nan Yuemin, the project leader, currently serves as the director of the Department of Hepatology of the Third Hospital of Hebei Medical University, integrating traditional Chinese and Western medicine. He is the chief physician/professor, doctoral supervisor, special allowance expert of the State Council, and a high-end talent in Hebei Province. Candidate Chairman of the Hepatology Credit Association of the Chinese Medical Association, Vice Chairman of the Hepatology Expert Committee of the Chinese Association of Integrated Traditional and Western Medicine Doctors, Vice Chairman of the Cancer Metabolism Professional Committee of the Chinese Anti Cancer Association, and Executive Director of the Asia Pacific Medical Bioimmunology Society. He has long been engaged in the research on the pathogenesis of chronic liver disease and liver fibrosis, liver histopathology diagnosis, new molecular diagnosis and treatment technology, and the prevention and treatment scheme of integrated traditional and western medicine. Undertake and complete 28 national and provincial level scientific research projects, with a vertical research funding of 3.69 million yuan. Received 2 first prizes for scientific and technological progress in Hebei Province, 8 third prizes for scientific and technological progress in Hebei Province, and 9 awards for scientific and technological progress and excellent medicine from the Department of Health and Education of Hebei Province. Published over 70 SCI/ISIP papers. There are 10 vocational talents in the research team, with 10 holding doctoral degrees. This research room is the "Key Laboratory for the Research of Liver Fibrosis Mechanism of Chronic Liver Disease in Hebei Province", the "Key Laboratory for the Research of Traditional Chinese Medicine in Hebei Province", the "Eleventh Five Year Plan" Key Liver Disease Specialty of the National Administration of Traditional Chinese Medicine, the key discipline of gastroenterology in Hebei Province, and the key specialty of traditional Chinese medicine in Hebei Province. It has abundant research technology, theory, and talent resources, and won the National Natural Science Foundation of China from 2018 to 2019 The Hebei Province Minsheng Science and Technology Special Key R&D Plan project and other funding funds of 1.5 million yuan can support the completion of various experiments and clinical studies. Our research laboratory has facilities such as pathology laboratory, molecular biology laboratory, immune laboratory, cell culture room, traditional Chinese medicine research room, decoction room, specimen library, and reference room. Possess conditions for conducting molecular biology, pathology, cell culture, gene modification, and screening and preparation of traditional Chinese medicine formulas. The supporting unit has high-end experimental instruments such as electron microscopes, fully automated biochemical analyzers, and flow cytometry, which can support the completion of relevant research. The clinical research conditions include 60 specialized outpatient and ward beds that meet the clinical research conditions, ultrasound detectors, Fibroscan, Fibrotouch detectors, electronic endoscopes, and magnetic resonance imaging, which can ensure the implementation and efficacy evaluation of clinical research. The application of high-throughput sequencing technology and the analysis, verification and clinical transformation of results Introduce high-level technical talents and international leading technologies, and realize the transformation of biological information technology achievements into clinical applications. 1. Screen differentially expressed genes of chronic hepatitis, liver fibrosis and related liver cancer, and verify the diagnostic efficacy of key genes in hepatitis related liver fibrosis and related liver cancer through clinical standard and in vitro experiments, To provide a theoretical basis for the precise diagnosis of liver fibrosis and related liver cancer, and to develop a new ELISA kit for the diagnosis of liver fibrosis and related liver cancer. 2. After screening a series of differentially expressed genes in the serum of patients with chronic hepatitis, liver fibrosis and related liver cancer, we aim to seek molecular diagnostic markers with predictive liver cancer risk and potential targets for gene therapy of liver fibrosis and related liver cancer, Provide new treatment strategies for drug research and development of hepatitis, liver fibrosis, and related liver cancer. 3. Further clarify the new mechanism of self-developed Yiqi Huoxue Formula for anti liver fibrosis, and evaluate the efficacy of anti liver fibrosis, providing new options for traditional Chinese medicine treatment of liver fibrosis and related liver cancer. Chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) are one of the main diseases that seriously endanger human health. China's population of chronic liver diseases accounts for 30.23% of the global population, and their typical progression process is the three-step process of chronic hepatitis liver fibrosis/cirrhosis hepatocellular carcinoma. Early detection, accurate diagnosis, and timely implementation of effective measures are the key to preventing/delaying their progression. At present, the commonly used diagnostic methods of liver imaging and liver histopathology have some limitations. Molecular biology diagnostic technology has developed rapidly and has gradually been applied in clinical practice, but its application in the grading and staging diagnosis of liver fibrosis and liver cancer is still limited. By combining modern molecular detection technology, developing serological diagnostic markers with high sensitivity and specificity, and establishing a new diagnostic model based on them, it will help improve the accurate diagnosis rate of the disease, guide clinical treatment and early prevention and control, and improve the diagnosis and treatment level of chronic liver disease in China, It can also provide scientific basis for the research and application of clinical drugs.